Islam and Humanitarian Action: Prospects and Challenges 

Islamabad, November 29, 2021 (PPI-OT):Humanitarian actions and services form the very core of Islamic philosophy and principles and this is not only evident from the commandments of Allah and the teachings of Quran, but also manifested by the Prophet Mohammad (PBUH) via his actions throughout his life.

These views were expressed by speakers during a two-day national conference titled ‘Islam and Humanitarian Action: Prospects and Challenges’, which was jointly organized by International Committee of the Red Cross (ICRC) and Institute of Policy Studies (IPS), Islamabad at a private hotel in Karachi on November 24-25, 2021.

The conference, which saw researchers from different universities, seminaries and social welfare organizations from across the country presenting their dissertations, was attended by renowned ulema as well as heads and representatives of national and international social welfare organizations.

The first day of the event was graced by Mufti Muneeb-ur-Rahman, president, Tanzeem-ul-Madaris Pakistan, as a chief guest. Many ulema including Maulana Yaseen Zafar from Faisalabad, Mufti Abdul Munim from Karachi, Molvi Abdullah Khoso from Kashmore, Mohammad Rafiq Shinwari from Peshawar, Dr Mohammad Tariq Ramzan from Sargodha, and Dr Ashfaq Ahmad from Islamabad presented their research papers on the occasion, before Chairman IPS Khalid Rahman, Vice Chairman IPS Ambassador (r) Syed Abrar Hussain, Dr Zia ullah Rahmani, regional advisor on Islamic law and fiqh, ICRC, Maulana Dr Ahmad Binori from Jamiatul Uloom Al-Islamia, Binori Town, Karachi, Shujauddin Sheikh from Tanzeem-e-Islami, Pakistan, and renowned educationist and scholar Dr Syed Mohsin Naqvi shared their views.

On the concluding day of the conference, Abdul Shakoor, president, Al-Khidmat Foundation Pakistan, Kanwar Waseem, provincial secretary, Red Crescent Pakistan, Prof Dr Anis Ahmed, vice chancellor, Riphah International University (RIU), Islamabad and Maulana Mufti Abdul Raheem from Jamia Rasheed, Karachi chaired separate sessions. Dr Shehzad Channa and Raheela Khan Advocate from Karachi, Dr Umar Saleem, Dr Maleeha Zeba Khan and Hafiz Usama Hameed from Islamabad and Aqsa Tasgheer from Lahore presented their papers whereas Maulana Hanif Jalandhari, nazim-e-aala, Wafaq-ul-Madaris Alarbia Pakistan, Umair Hassan, head of Islamic Relief UK, Abdul Shakoor, Al-Khidmat Foundation, Dr Fayyaz Alam, Dua Foundation, Dr Shahida Nomani, Shaoor Welfare Trust, Umair Siddiqui, member of Council of Islamic Ideology (CII), Maulana Dr Zubair Ashraf Usmani from Darul Uloom Karachi, Dr Syed Aziz-ur-Rehman and Dr Sohail Akhtar, former president of Pakistan Islamic Medical Association (PIMA) expressed their views following the papers presentation.

In the opening ceremony of the conference, Mufti Muneeb-ur-Rehman stressed that extending help to the needy in the hour of grief is not only Allah’s commandment in the Qur’an but it was also reflected by the Prophet’s (PBUH) through practice all his life. This was also emphasized by the Prophet (PBUH) in his farewell sermon which teaches Muslims equality and empathy, he added.

Underlining the role of religious scholars and ulema in humanitarian services, Mufti Muneeb was of the view that it is the fundamental obligation of Muslim religious scholars to support every victim of oppression in the world. The scholar also urged the United States and the European community to lift financial sanctions imposed on Afghanistan following the ascension of the Taliban to power in Kabul, in order to avoid the humanitarian crisis that might befall upon the war-hit country if the financial support required for running state affairs is not provided.

Mufti Muneeb also ruled that some powers want to achieve their nefarious goals under the guise of humanitarian services. He warned that such actions would malign the noble cause and dishearten those humanitarian workers who are genuinely striving for creating a better world for future generations.

Sharing his views on the second day, Maulana Jalandhri said that the crux of Islam, according to most credible ulemas, lies in the obedience of the Almighty, following of the Prophet’s teachings and serving of humanity. A living example of this, according to him, could be seen in form of many humanitarian organizations which are working in the name of Islam and making collective efforts to serve humanity. He further added that the madrassas and religious seminaries in the country are not only providing religious education to millions of poor, orphaned and needy students, but are also a source of sustenance for them.

Referring to Wafaq-ul-Madaris Alarabia Pakistan, Hanif Jalandhari said that about 23000 madrassas from all over the country are affiliated with this Wafaq alone, benefiting more than 2.5 million students across Pakistan; and this data is from only one Wafaq, he pointed, while other Wafaqs could present similar stats of their own. This underscores how these Wafaqs and madaris are playing not only the role of religious educational institutions, but also that of social welfare organizations.

Abdul Shakoor said social service organizations including Al-Khidmat are active for humanitarian service in the light of Islamic teachings and are committed to serving people, both Muslims and non-Muslims alike, in Pakistan as well as abroad, without any discrimination or hidden interest. Addressing the session, Mufti Abdul Raheem said the solution to the problems being faced by humanity lies in following the path set by the Holy Prophet (PBUH), and stressed the need for eradicating depression and anxiety in today’s world.

Referring to the minorities, he warned if non-Muslims living in Pakistan are insecure then the Muslims across the globe would also be in distress. He underlined the importance of human compassion in Islam by saying that even in times of war, the agreements made with the infidels were implemented in letter and spirit and the infidels were also helped in their difficulties when needed. He deplored the gulf of misunderstanding lying between seminaries and NGOs and believed that this mistrust must be bridged.

Dr Maleeha Zeba Khan, non-resident fellow at IPS and assistant professor at National University of Modern Languages (NUML) presented an interesting dissertation highlighting that about three quarters of the land is water based and a large number of people have been using these sea routes since times immemorial for maritime trade, fishing and security.

The presence of such a large number of people at sea for these various purposes also poses a variety of threats to them in form of natural disasters such as tsunamis and hurricanes, as well as human trafficking, piracy and other crimes, or accidents involving boats, ships or fishermen. She opined that the humanitarian services rendered within the oceans by law enforcement agencies such as the Pakistan Maritime Security Agency (PMSA) must also be appreciated in this regard. Concluding the conference, Dr Zia ullah Rahmani on behalf of ICRC and Khalid Rahman on behalf of IPS thanked the participants and hoped such endeavours would continue in the future as well.

For more information, contact:
Outreach and Publications,
Institute of Policy Studies (IPS)
1, Street 8, F-6/3, Islamabad, Pakistan
Tel: +92-51-8438391-3 (Ext: 122)
Fax: +92-51-8438390
Website: www.ips.org.pk

HEC Team visits Smart Wifi Campus at IIUI 

Islamabad, November 29, 2021 (PPI-OT):A team of Higher Education Commission (HEC), led by Mr. Nazeer Hussain, Director General I.T. along with Director Pakistan Education and Research Network (PERN) Mr. Abdul Fayyaz Chattha, Director I.T. The team visited the newly created smart class rooms in male and female campuses.

D.G. IT, Mr. Nazeer Hussain congratulated the efforts of IIUI in establishment of Smart Wifi Campus in male and female campuses. The team was briefed by Dr. Asim Munir, Chairman, Department of Computer Science and Director IT. Saleem Shahzad. Mr. Shahid Mehmood, Dy. Director Networks and Mr. Muhammad Ali, Assistant Director Networks were also present on the occasion.

For more information, contact:
Public Relations,
International Islamic University Islamabad (IIUI)
Room No.118, Admin Block, New Campus,
H-10 Sector, Islamabad, Pakistan
Tel: +92-51-9019249
Fax: +92-51-9257909
Email: iiuipublicrelations@iiu.edu.pk
Website: www.iiu.edu.pk

A Ground-breaking Collaboration

Lahore, November 29, 2021 (PPI-OT):Responding to an invitation from the University of Baltistan, a team of senior administrators and faculty from LUMS spent a week in Skardu in great anticipation of establishing a landmark partnership. During the scenic flight, good weather revealed spectacular views of the Himalayas and the K2. Unfortunately, the snow melt in recent years and its impact on the ground poses an existential threat to many of the local communities. In 2019, Gilgit recorded 27 geological disasters spawned by climate change.

Just recently, countries around the world met at the Glasgow Climate Change Conference to discuss the impact of global warming and the importance of collaboration for innovative climate action across all of society, sectors, and regions.

Dialogue between LUMS officials, the University of Baltistan and public officials was no different during the week-long visit to Skardu. Unique presentations complemented by local excursions revealed how both universities could effectively support and learn from each other to combat climate change.

LUMS presentations to university leadership, Dr. Ashfaq Ahmad, Dean of Social Science and Education, and faculty at both the Sundus and Anchan campuses were well-received. Interactive presentations from Associate Professors Dr. Abubakr and Dr. Naveed, Assistant Professor Dr. Adnan Zahid, and past president of the Student Council, Hattaf Ayub highlighted our preliminary areas of focus. LUMS Vice Chancellor Dr. Arshad Ahmad also spoke to several audiences about the National Outreach Programme, including high school and college students who were also in attendance.

Cutting edge research at the LUMS Centre for Water Informatics and Technology is an excellent example of how faculty from business, social sciences, engineering, and science work as a team to address the most pressing issues in the water sector. The same can be said for the LUMS Energy Institute for green initiatives. LUMS is convinced these interventions to address grand challenges require solutions from multiple disciplines. A liaison between LUMS and the University of Baltistan would provide the much-needed research required for gathering accurate data to determine how to use water more efficiently, explore glacial grafting and policy considerations for developing the power sector.

The collaboration also focuses on students from both campuses. Five courses will be introduced in Skardu next July to address how entrepreneurship as well as jobs in the fields of heritage preservation and hospitality management can be amplified. The tourism boom in Skardu has already revealed the need for capacity development in these areas as well as digital e-commerce. Accordingly, SDSB and REDC are already planning interventions that can be scaled up in the future.

The exchange programme kicks off on December 10th when 10 faculty from the University of Baltistan will meet with faculty at LUMS to discuss the co-creation of courses and instructional strategies for co-teaching. Next July, the first cohort of 150 LUMS students will be paired with students from the University of Baltistan with faculty from both institutions. The result will be a mutually beneficial partnership that transfers knowledge, expertise, experience, skills, and resources in both directions.

For more information, contact:
Lahore University of Management Sciences (LUMS)
D.H.A. Lahore Cantt. 54792
Lahore, Pakistan
Tel: +92-42-35608000
Fax: +92-42-35725048
Website: www.lums.edu.pk

54% Pakistanis hold the opinion that the ban on Basant (kite-flying) in Pakistan should not be lifted; old (63%) respondents are relatively more likely to feel this way: Gallup and Gilani Pakistan 

Islamabad, November 29, 2021 (PPI-OT):According to a survey conducted by Gallup and Gilani Pakistan, 54% Pakistanis hold the opinion that the ban on Basant (kite-flying) in Pakistan should not be lifted; old (63%) respondents are relatively more likely to feel this way.

A nationally representative sample of adult men and women from across the four provinces was asked the following question, “Do you think the ban on Basant (kite-flying) in Pakistan should be lifted?” In response to this question, 54% said no while 38% said yes. 8% did not know or provided no response.

Question: “Do you think the ban on Basant (kite-flying) in Pakistan should be lifted?”

For more information, contact:
Head Office,
Gallup Pakistan
Islamabad, Pakistan
Tel: +92-51-8445080
Email: isb@gallup.com.pk, caf@gallup.com.pk
Website: www.gallup.com.pk

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing

ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022

Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection.

“The continued global scale of the COVID-19 pandemic has led to increased levels of immune pressure on the virus, which is driving the emergence of variants containing mutations associated with escape from common classes of neutralizing antibodies induced by natural infection or vaccination. Unlike most antibodies currently available under EUA, ADG20 has been shown to target an epitope that is highly conserved among clade I sarbecoviruses and that is not readily targeted by the endogenous neutralizing antibody response,” said Laura Walker, Ph.D., co-founder and chief scientific officer of Adagio. “Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously. Further, none of the mutations present in the spike protein of the Omicron variant have been associated with escape from ADG20 neutralization.   ADG20 was engineered for potent and broadly neutralizing activity in anticipation of both the rapid antigenic evolution of SARS-CoV-2 and the emergence of future SARS-like viruses with pandemic potential.”

“ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS-CoV-2 for up to one year in a single injection. We did this anticipating that SARS-CoV-2 would continue to evolve and potentially render some early therapies and vaccines obsolete,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our global clinical trials are advancing with potential EUA submissions in mid-2022 for both prevention and treatment of COVID-19. We continue to engage with the FDA and other regulatory bodies and governmental agencies to discuss potential acceleration of development plans and the need for a portfolio of therapeutic solutions to combat the COVID-19 pandemic.”

Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20’s utility in addressing this newly emerged variant of concern, including:

  • Conducting in vitro studies to evaluate the expected binding and neutralizing activity of ADG20 against Omicron. Initial data from these studies is anticipated by the end of the year; and
  • Recruiting patients in Adagio’s Phase 2/3 COVID-19 treatment trial, known as STAMP, across several clinical sites in South Africa (along with ongoing clinical trial efforts globally) in an effort to generate clinical data for ADG20 against infections due to the Omicron variant.

Based on the data being generated, Adagio plans to engage with health authorities and government agencies to accelerate development and supply of ADG20 to combat SARS-CoV-2 and its variants of concern.

ADG20 and Variants of Concern
The neutralizing antibody response induced by SARS-CoV-2 infection and vaccination is dominated by three classes of receptor binding domain (RBD)-directed antibodies (Class 1, Class 2 and Class 3), which often share common escape mutations. The newly emerged Omicron (B.1.1.529) variant identified in South Africa contains mutations associated with resistance to a large proportion of these commonly elicited antibodies, which may be due to immune pressure on these antigenic sites. Data for most antibodies available under EUA or in late-stage clinical development show they target one of these three dominant antigenic regions within the RBD.

In vitro studies have shown that ADG20 binds to a highly conserved epitope within the RBD that is not targeted by any of the common classes of neutralizing antibodies induced by SARS-CoV-2 infection and vaccination. Thus, unlike many other clinical-stage antibodies, which were isolated from COVID-19 patients and recognize epitopes that are also targeted by endogenous neutralizing antibodies, there is limited immune pressure on the ADG20 binding site. The ADG20 epitope has remained conserved in 99.99% of the nearly 4 million full length SARS-CoV-2 viral sequences deposited in the GISAID database as of October 15, 2021, and, as shown in in vitro studies, ADG20 retains activity against prior variants of concern including Alpha, Beta, Delta, and Gamma. For the Omicron variant, none of the mutations present in the spike protein are associated with escape from ADG20 neutralization. Based on published epitope mapping and structural studies, Adagio anticipates that ADG20 will retain neutralizing activity against the Omicron variant whereas other mAb products may lose substantial activity against this variant.

Previously disclosed in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the recently emerged Lambda, Mu and Delta plus variants. Notably, findings from these in vitro studies showed that ADG20 demonstrated potent neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late-stage development.

About ADG20
ADG20, an investigational monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS-CoV-2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half-life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS-CoV-2 virus, SARS-CoV-2 variants of concern Alpha, Beta, Delta, and Gamma, other SARS-CoV-2 variants to date, and additional SARS-like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well-tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow-up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the expected neutralizing activity of ADG20 against the Omicron variant; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the risk/benefit profile of our product candidates to patients; our manufacturing capabilities and strategy, including plans for doses available in the near future; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic.  Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

بائیس ییہاؤ: گوانگژی کے مقام بائیس سے شروع ہونے والی سروس جو پورے ملک کا احاطہ کرتی ہے اور آسیان سےجا مِلتی ہے

بیس، چین، 29 نومبر، 2021/سنہوا-شینژین/– ، بائیس شہر کے تشہیری محکمے کے مطابق، حال ہی میں، بیس-شینزین کولڈ چین لاجسٹکس اسپیشل لائن کی “بائیس ییہاؤ” (“Baise Yihao” ) خصوصی ٹرین کی لانچنگ تقریب چین-آسیان زرعی مصنوعات کے تجارتی مرکز میں منعقد ہوئی، جس میں بائیس کی زرعی مصنوعات باضابطہ طور پر کولڈ چین لاجسٹکس اسپیشل ٹرین کے ذریعے شینزین مارکیٹ میں داخل ہوئیں اور بائیس کے لیے  گوانگڈو-ہانگ کانگ-مکاؤ گریٹر بے ایریا(جی بی اے) کی ترقی میں گہرائی سے شامل ہونے کا ایک اور موثر ذریعہ بن گئیں۔

عنوان : “بائیس سٹی” خصوصی ٹرین کو لفٹ کیا جا رہا ہے۔

بائیس سٹی “سبزیوں کی جنوب سے شمال تک نقل و حمل” کے لیے ایک مشہور مقام ہے جہاں  ہر سال 3 ملین سے زیادہ ماحولیاتی سبزیاں لگائی جاتی ہیں۔ 11 دسمبر 2013 کو اس کے باضابطہ آغاز کے بعد سے، “بائیس ییہاؤ” کولڈ چین اسپیشل ٹرین، بطور قومی پروجیکٹ “سبزیوں کی جنوب سے شمال اور پھلوں کی شمال سے جنوب میں نقل و حمل “کے ذریعےلوگوں کو فائدہ پہنچا رہا ہے،  اس نے نہ صرف بائیس میں پیدا ہونے والے پھلوں اور سبزیوں کو 100 سے زیادہ بڑے اور درمیانے درجے کے شہروں، 23 صوبوں اور بیجنگ، شنگھائی اور گوانگزو جیسے خود مختار علاقوں تک پہنچایا ہے، بلکہ بہت سے  ایسے پھلوں اور سبزیوں کی فروخت کے مسائل کو بھی حل کیا ہے جن کی  بائیس میں قیمتیں کم  تھیں،جس سے  کسانوں کی آمدنی میں اضافہ ہوا۔  مزید برآں، یہ  پراجیکٹ زرعی مصنوعات کی نقل و حمل میں انقلابی تبدیلیاں بھی لایا ، اور غربت کے خاتمے اور اس نے  دیہی حیاتِ نو میں زبردست کردار ادا کیا ہے۔

دریں اثنا، “بائیس ییہاؤ” کی منفرد جغرافیائی خصوصیات کے ساتھ، بائیس ییہاؤ سمندری ریل اور عوامی ریل کی سرحد پار نقل و حمل کے لیے ایک کثیر المثال ٹرانسپورٹ سسٹم قائم کیا گیا ہے جن میں لانگ بینگ، پنگشیانگ اور فانگ چینگ گانگ شامل ہیں، جس نے اسے بائس ییہاؤ کو پھلوں اور سبزیوں کی خصوصی گھریلو ٹرین بنا دیا گیا ہے۔ بائیس ییہاؤ چین-ویتنامی سرحد پار براہ راست نقل و حمل ٹرین چین-یورپ ریلوے ایکسپریس کے کھُلے  شہروں جیسے چونگ کنگ، چینگڈو، ووہان، ژینگ زو اور بیجنگ کے ساتھ ساتھ سیچوان، گوئژو ، اور گوانگسی میں جنوب کی طرف جانے والے راستوں کے کھلے شہروں کو باضابطہ طور پر ملاتی ہے اور پورے ملک اور یہاں تک کہ ساری دنیا میں”بائیس ییہاؤ” کے اثر و رسوخ کو بڑھا رہی ہے۔ “بائیس ییہاؤ” پروجیکٹ کو وزارت ٹرانسپورٹ نے یوریشیا میں کولڈ چین لاجسٹکس چینل کی تعمیر کے پہلے قومی نمائشی منصوبے کے طور پر درج کیا ہے۔ اس کے علاوہ، بائیس ییہاؤ کولڈ چین لاجسٹکس سسٹم کو بیلٹ اینڈ روڈ انیشیٹو میں کامیابی کے ساتھ ضم کر دیا گیا ہے۔

اس وقت ، بائیس ییہاؤ نے  بائیس، نیننگ، فانگچینگانگ، پنگشیانگ، شینزین، بینجگ،  لینگ فانگ، تیانجن، شینیانگ، ژینگزو، ووہان، چانگچنگ، چینگڈو، ہوچی منھ شہر،  ہنوئی، پھنوئی پینھ،، بینکاکم وغیرہ میں  پھلوں اور سبزیوں کے لیے خصوصی رسد کی تقسیم کے مراکز قائم کیے ہیں۔  اپنے وسیع نیٹ ورک پر انحصار کرتے ہوئے، بائیس ییہاؤ نےگوانگزی کے مقام بائیس سے آغاز کرنے کا ہدف حاصل کیا ہے،   یہ پورے ملک پر اثر انداز ہوتی ہے  اور آسیان(ASEAN) سے جا ملتی ہے۔

2013 کے آخر میں اپنے افتتاح کے بعد سے، “بائیس ییہاؤ” ڈومیسٹک اسپیشل ٹرین تقریباً 116,000 ٹن کے کل مال برداری سامان کے ساتھ 233 بار سفر کرچکی ہے۔ 28 نومبر 2017 کو  بائیس ییہاؤ  چین-ویتنامی سرحد پار براہ راست ٹرانسپورٹ ٹرین کے افتتاح کے بعد سے اب تک  69,000 ٹن کے کل مال بردار حجم کے ساتھ 164 ٹرپس چلائے جا چکے  ہیں۔

ماخذ: بائیس سٹی کا تشہیری محکمہ

منسلک تصاویر ی لنکس:  http://asianetnews.net/view-attachment?attach-id=408997